Cannabinoids, immune system and cytokine network

Current Pharmaceutical Design

Volumn 12, Issue 24, 2006, Pages 3135-3146

  Massi, P ^a   Vaccani, A ^b   Parolaro, Daniela ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Cannabinoid receptors; Cannabinoids; Cytokines; Endogenous cannabinoids; Immune response; Signaling; Tetrahydrocannabinol

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ADENYLATE CYCLASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; CD4 ANTIGEN; CD8 ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOKINE; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; NITRIC OXIDE; PALMIDROL; RIMONABANT; TETRAHYDROCANNABINOL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALGESIA; ANTIBODY PRODUCTION; ASTROCYTE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BRAIN INJURY; BRAIN REGION; BRONCHITIS; CANNABIS ADDICTION; CARCINOGENESIS; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG STRUCTURE; ENZYME ACTIVATION; HEMATOPOIETIC CELL; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; INFECTION RESISTANCE; INFLAMMATION; LUNG LAVAGE; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MAST CELL; MOUSE; MURINE ENCEPHALOMYELITIS VIRUS; NATURAL KILLER CELL; NEUROPROTECTION; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTOZOAL INFECTION; RECEPTOR UPREGULATION; REVIEW; ROSETTE FORMATION; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; THEORY; TUMOR IMMUNITY; VIRUS INFECTION;

ANIMALS; CANNABINOIDS; CYTOKINES; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; SIGNAL TRANSDUCTION;

EID: 33747177333     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777947425     Document Type: Review

References (102)

1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
2. Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279: 129-134.
3. Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 1992; 42: 736-742.
4. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, et al. Cannabinoid receptor expression in human leukocytes. Eur J Biochem 1993; 214: 173-180.
5. Schatz AR, Lee M, Condie R, Pulaski J, Kaminski NE. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 1997; 142: 278-287.
6. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissue and leukocyte subpopulations Eur J Biochem 1995; 232: 54-61.
7. Sinha D, Bonner TI, Bhat NR. Matsuda LA. Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies. J Neuroimmunol 1998; 82: 13-21.
8. Daaka Y, Friedman H, Klein TW. Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. J Pharmacol Exp Ther 1996; 276: 776-783.
9. Daaka Y, Klein TW, Friedman H. Expression of cannabinoid receptor mRNA in murine and human leukocytes. Adv Exp Med Biol 1995; 373: 91-96.
10. Massi P, Patrini G, Rubino T, Fuzio D, Parolaro D. Changes in rat spleen cannabinoid receptors after chronic CP-55,940: an autoradiographic study. Pharmacol Biochem Behav 1997; 58: 73-78.
11. Manzanares J, Corchero J, Fuentes JA. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of THC in rats. Brain Res 1999; 839: 173-179.
12. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 346: 561-564.
13. Nong L, Newton C, Cheng Q, Friedman H, Roth MD, Klein TW. Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J Neuroimmunol 2002; 127: 169-176.
14. Carayon P, Marchand J, Dussossoy D, Derocq JM, Jbilo O, Bord A, et al. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 1998; 15: 3605-3615.
15. Marchand J, Bord A, Penarier G, Laure F, Carayon P, Casellas P. Quantitative method to determine mRNA levels by reverse transcriptase-polymerase chain reaction from leukocyte subsets purified by fluorescence-activated cell sorting: application to peripheral cannabinoid receptors. Cytometry 1999; 35: 227-234.
16. Lynn AB, Herkenham M. Localization of cannabinoid receptors and non saturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994; 268: 1612-1623.
17. Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lip 2000; 108: 169-190.
18. Lee SF. Newton C. Widen R. Friedman H. Klein TW. Differential expression of cannabinoid CB2 receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. Eur J Pharmacol 2001; 423: 235-241.
19. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2002; 2: 69-82.
20. Matias I, Pochard P, Orlando P, Salzet M, Pestel J, Di Marzo V. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 2002; 269: 3771-3778.
21. Salzet M. Breton C, Bisogno T, Di Marzo V. Comparative biology of the endocannabinoid system. Eur J Biochem 2000; 267: 4917-4927.
22. Parolaro D, Massi P, Rubino T, Monti E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 319-332.
23. Sugiura T, Kondo S, Kishimoto S. Evidence that 2-arachidonoyl-glycerol but not N-palamitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligand in HL-60 cells. J Biol Chem 2000; 275: 605-612.
24. Kishimoto S, Gokoh M, Muramatsu M, Kajiwara T, Waku K, Sugiura T. 2-arachidonoilglicerol induces the migration of HL-60 cells differentiated into macrophages-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J Biol Chem 2003; 278: 24469-24475.
25. Pertwee RG, Ross RA. Cannabinoids receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 101-122.
26. 9-THC): a putative mechanism of cannabinoid-induced immune modulation. Biochem Pharmacol 1997; 53: 1477-1484.
27. Herring AC, Koh WS, Kaminski NE. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and κB elements by cannabinol, a minimally CNS-active cannabinoid. Biochem Pharmacol 1998; 55: 1013-1023.
28. Schatz AR, Kessler FK, Kaminski NE. Inhibition of adenylate cyclase by Δ-9-tetrahydrocannabinol in mouse spleen cells: a potential mechanism for cannabinoid-mediated immunosuppression. Life Sci 1992; 51: 25-30.
29. Condie R, Herring A, Koh WH, Lee M, Kaminski NE. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and IL-2 expression in the murine T-cell line, EL4.IL-2. J Biol Chem 1996; 271: 13175-13183.
30. Jeon YJ, Yang KH, Pulaski JT, Kaminski NE. Attenuation of iNOS gene expression by delta-9-tetrahydrocannabinol is mediated through the inhibition of NF-κB/Rel activation. Mol Pharmacol 1996; 50: 334-341.
31. Yea SS, Yang KH, Kaminski NE. Role of nuclear factor of activated T-cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. J Pharmacol Exp Ther 2000; 292: 597-605.
32. Herring AC, Kaminski NE. Cannabinol-mediated inhibition of nuclear factor- kB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. J Pharmacol Exp Ther 1999; 291: 1156-1163.
33. Kaminski NE, Koh WH, Yang KH, Lee M, Kessler FK. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharmacol 1994; 48: 1899-1908.
34. Watson PA, Krupinski J, Kempinski AM, Frankenfield CD. Molecular cloning and characterization of the type VII isoform of mammalian adenylyl cyclase expressed widely in mouse tissues and in S49 mouse lymphoma cells. J Biol Chem 1994; 269: 28893-28898.
35. Feng W, Wang Y, Zhang J, Wang X, Li C, Chang Z. Effects of CTx and 8-bromo-cAMP on LPS-induced gene expression of cytokines in murine peritoneal macrophages. Biochem Biophys Res Commun 2000; 269: 570-573.
36. Koh WS, Yang KH, Kaminski NE. Cyclic AMP is an essential factor in immune responses. Biochem Biophys Res Commun 1995; 206: 703-709.
37. Waksman Y, Olson JM, Carlisle SJ, Cabral GA. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglia cells. J Pharmacol Exp Ther 1999; 288: 1357-1366.
38. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 1995; 375: 143-147.
39. Bayewitch M, Rhee MH, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 1996; 271: 9902-9905.
40. Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997; 17: 5327-5333.
41. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrie B, Rinaldi-Carmona M, et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Pharmacol 1996; 237: 704-711.
42. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995; 48: 443-450.
43. Kobayashi Y, Arai S, Waku K, Sugiura T. Activation by 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, of p42/44 mitogen-activated protein kinase in HL-60 cells. J Biochem 2001; 129: 665-669.
44. Faubert BL, Kaminski NE. AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. J Leukoc Biol 2000; 67: 259-266.
45. Klein T. Cannabis and Immunity. In: Kalant H. Corrigal W. Eds. The health effect of cannabis. Centre for addiction and mental health, Canada 1999: 349-373.
46. Tashkin DP, Baldwin GC, Sarafian T, Dubinet S, Roth MD. Respiratory and immunologic consequence of marijuana smoking. J Clin Pharmacol 2002; 42: 71S-81S.
47. Nahas GG. Morishima A. Desoize B. Effect of cannabinoids on macromolecular synthesis and replication of cultured lymphocytes. Fed Proc 1977; 36: 1748-1752.
48. Patrini G, Sacerdote P, Fuzio D, Manfredi B, Parolaro D. Regulation of immune function in rat splenocytes after in vivo treatment with CP-55,940, a synthetic cannabinoid compound. J Neuroimmunol 1997; 80: 143-148.
49. 9-tetrahydrocannabinol: functional and biochemical parameters. J Neuroimmunol 1998; 92: 60-66.
50. Klein TW, Kawakami Y, Newton C, Friedman H. Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J Toxicol Environ Health 1991; 32: 465-477.
51. Fischer-Stenger K, Updegrove AW, Cabral GA. Delta 9-tetra-hydrocannabinol decreases cytotoxic T lymphocyte activity to herpes simplex virus type 1-infected cells. Proc Soc Exp Biol Med 1992; 200: 422-430.
52. Rachelefsky GS, Opelz G, Mickey MR, Lessin P, Kiuchi M, Silverstein MJ, et al. Intact Immoral and cell-mediated immunity in chronic marijuana smoking. J. Allergy Clin Immunol 1976; 58: 483-490.
53. Nahas GG, Osserman EF. Altered serum immunoglobulin concentration in chronic marijuana smokers. Adv Exp Med Biol 1991; 288: 25-32.
54. Schwarz H, Blanco FJ, Lotz M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 1994; 55: 107-115.
55. Lee M, Yang KH, Kaminski NE. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther 1995; 275: 529-536.
56. Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Segui M, Casellas P. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett 1998; 425: 419-425.
57. Valk P, Verbakel S, Vankan Y, Hol S, Mancham S, Ploemacher R, et al. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. Blood 1997; 90: 1448-1457.
58. Berdyshev EV, Schmid PC, Dong Z, Schmid HHO. Experimentally relevant levels of N-acylethanolamines including anandamide are present in serum-containing cell culture media. FASEB J 1999; 13: A1378.
59. 9-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur J Pharmacol 2000; 387: 343-347.
60. Sherman MP, Campbell LA, Gong HJ, Roth MD. Tashkin DP. Respiratory burst and microbicidial characteristics of pulmonary alveolar macrophages recovered from smokers of marijuana alone, smokers of tobacco alone, smokers of marijuana and tobacco and nonsmokers. Am Rev Respir Dis 1991; 144: 471-501.
61. McCoy KL, Gainey D, Cabral GA. Delta 9-Tetrahydrocannabinol modulates antigen processing by macrophages. J Pharmacol Exp Ther 1995; 273: 1216-1223.
62. McCoy KL, Matveyeva M, Carlisle SJ, Cabral GA. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J Pharmacol Exp Ther 1999; 289: 1620-1625.
63. Sacerdote P. Massi P. Panerai AE. Parolaro D. In vivo and in vitro treatment with the synthetic cannabinoid CP-55,940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol 2000; 109: 155-163.
64. Pestonjamasp VK. Burstein SH. Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim Biophys Acta 1998; 1394: 249-260.
65. Varga K, Wagner JA, Bridgen T, Kunos G. Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998; 12: 1035-1044.
66. Berdyshev EV, Schmid PC, Krebsbach RJ, Kuwae T, Huang C, Ma WY, et al. Role of N-acylethanolamines in cell signaling. World Rev Nutr Diet 2001; 88: 207-214.
67. Cabral GA, Toney DM, Fischer-Stenger K, Harrison MP, Marciano-Cabral F. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci 1995; 56: 2065-2072.
68. Ross RA, Brockie HC, Pertwee RG. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur J Pharmacol 2000; 401: 121-130.
69. Chang YH, Lee ST, Lin WW. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem 2001; 81: 715-723.
70. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper D, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995; 92: 3376-3380.
71. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999; 6: 635-664.
72. Blanchard DK, Newton C, Klein TW, Stewart WE, Friedman H. In vitro and in vivo suppressive effects of delta-9-tetrahydrocannabinol on interferon production by murine spleen cells. Int J Immunopharmacol 1986; 8: 819-824.
73. Watzl B, Scuder P, Watson RR. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharm 1991; 13: 1091-1097.
74. Zheng ZM, Specter S, Friedman H. Inhibition by delta-9-tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages. Int J Immunopharmacol 1992; 14: 1445-1452.
75. 9-Tetrahydrocannabinol suppresses tumor necrosis factor alpha maturation and secretion but not its transcription in mouse macrophages. Int J Immunopharmacol 1996; 18: 53-68.
76. Klein TW, Friedman H. In: Watson R. Ed. Drugs of Abuse and Immune Function. Modulation of murine immune cells function by marijuana components. Boca Raton. CRC Press 1990; 87-111.
77. Zhu W, Newton C, Daaka Y, Friedman H, Klein TW. Delta 9-Tetrahydrocannabinol enhances the secretion of interleukin 1 from endotoxin-stimulated macrophages. J Pharmacol Exp Ther 1994; 270: 1334-1339.
78. Klein TW, Newton C, Widen R, Friedman H. Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J Pharmacol Exp Ther 1993; 267: 635-640.
79. Klein TW, Newton C, Friedman H. Inhibition of natural killer cell function by marijuana components. J Toxicol Envir Health 1987; 20: 321-332.
80. 9-tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or anti-CD3 antibody. Proc Soc Exp Biol Med 1992; 201: 165-168.
81. Zhu W, Igarashi T, Qi ZT, Newton C, Widen RE, Friedman H, et al. Delta-9-tetrahydrocannabinol (THC) decreases the number of high and intermediate affinity IL-2 receptors of the IL-2 dependent cell line NKB61A2. Int J Immunopharm 1993; 15: 401-408.
82. Zhu W, Igarashi T, Friedman H, Klein TW. Δ9-tetrahydrocannabinol (THC) causes the variable expression of IL-2 receptor subunits. J Pharmacol Exp Ther 1995; 274: 1001-1007.
83. Newton CA, Klein TW, Friedman H. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Immun 1994; 62: 4015-4020.
84. Klein TW, Newton CA, Nakachi N, Friedman H. Delta 9 tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol 2000; 164: 6461-6466.
85. Sacerdote P, Martucci C, Vaccani A, Bariselli F, Panerai AE, Colombo A, et al. The non-psychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol 2005; 159: 97-105.
86. Croxford JL, Miller SD. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid. R(+) WIN 55,212. J Clin Invest 2003; 111: 1231-1240.
87. Mestre L, Correa F, Arèvalo-Martin A, Molina-Holgado E, Valenti M, Ortar G, et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 2005; 92: 1327-1339.
88. Killestein J, Hoogervost ELJ, Reif M, Blauw B, Smits M, Uitdehaag BMJ, et al. Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. J Neuroimmunol 2003; 137: 140-143.
89. Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 2002; 133: 124-131.
90. Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 2000; 165: 373-380.
91. Srivastava MD, Srivastava BI, Brouhard B, Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998; 40: 179-185.
92. Tindall B, Cooper DA, Donovan B, Barnes T, Philpot CR, Gold J, et al. The Sydney AIDS Project: development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men. Aust N Z J Med 1988; 18: 8-15.
93. Zhang ZF, Moregenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR, et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 1999; 8: 1071-1078.
94. Roth MD, Baldwin GC, Tashkin DP. Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids 2002; 121: 229-239.
95. Derocq JM, Jbilo O, Bouaboula M, Segui M, Clere C, Casellas P. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J Biol Chem 2000; 275: 15621-15628.
96. Ihenetu K, Molleman A, Parsons M, Whelan C. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. Eur J Pharmacol 2003; 464: 207-215.
97. Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000; 29: 58-69.
98. Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 1992; 42: 838-845.
99. Molina-Holgado F, Molina-Holgado E, Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 1998; 433: 139-142.
100. Biegon A. Cannabinoids as neuroprotective agents in traumatic brain injury. Curr Pharm Des 2004; 10(18): 2177-83.
101. Kozak KR, Prusakiewicz JJ, Marnett LJ. Oxidative metabolism of endocannabinoids by COX-2. Curr Pharm Des 2004; 10(6): 659-67.
102. Vandevoorde S, Lambert DM. Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets. Curr Pharm Des 2005; 11(20): 2647-68.